🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 7521475

Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7517987

Caspase inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7514448

Azaindoles useful as inhibitors of rock and other protein kinases

Vertex Pharmaceuticals Incorporated · Granted Tue Apr 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7511038

Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors

Laboratories Almirall, S.A. · Granted Tue Mar 31 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7510710

Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a g

The Regents of the University of Colorado · Granted Tue Mar 31 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7507826

Azaindoles useful as inhibitors of JAK and other protein kinases

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7504430

Maleiimide anti-tumor phosphatase inhibitors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7501415

Selective inhibitors of ERK protein kinase and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7498337

Acid secretion inhibitor

Takeda Pharmaceutical Company Limited · Granted Tue Mar 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7495014

Gyrase inhibitors and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7494988

Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7491730

Compositions useful as inhibitors of GSK-3

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7488727

Thiazole compounds useful as inhibitors of protein kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7485664

Inhibitors of TACE

Vertex Pharmaceuticals Incorporated · Granted Tue Feb 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7482002

Method of administering and using VEGF inhibitors for the treatment of prostate cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479274

Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinom

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479272

Method of administering and using VEGF inhibitors for the treatment of breast cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479275

Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479273

Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7470790

Heteroaromatic selective inhibitors of neuronal nitric oxide synthase

Northwestern University · Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7470700

Dipeptidyl peptidase inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7470776

Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof

The Board of Regents of the University of Oklahoma · Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7468379

Inhibition of osteolytic lesions by SRC kinase inhibitors

The Board of Regents of the University of Texas System · Granted Tue Dec 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7462612

Pyridine inhibitors of ERK2 and uses thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Dec 09 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 04 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted